Drug resistance

Internal medicine

Proteasome

Immunotherapy

Plasmacytoma

Monoclonal antibody

Biology

Microbiology

Antibody

Multiple myeloma

Immunology

Drug class

Bortezomib

Drug

Drug development

Cell biology

Plasma cell neoplasm

Chimeric antigen receptor

Cancer research

Clinical trial

Medicine

Immune system

Pharmacology

Cancers

Multiple myeloma is a malignant plasma cell neoplasm that remains incurable and is ultimately fatal when patients acquire multi-drug resistance. Thus, advancing our understanding of the mechanisms behind drug resistance in multi-relapsed patients is critical for developing better strategies to extend their lifespan. Here, we review the understanding of resistance to the three key drug classes approved for multiple myeloma treatment: immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. We consider how the complex, heterogenous biology of multiple myeloma may influence the acquisition of drug resistance and reflect on the gaps in knowledge where additional research is needed to improve our treatment approaches. Fortunately, many agents are currently being evaluated preclinically and in clinical trials that have the potential to overcome or delay drug resistance, including next-generation immunomodulatory drugs and proteasome inhibitors, novel small molecule drugs, chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies. For each class, we discuss the potential of these strategies to overcome resistance through modifying agents within each class or new classes without cross-resistance to currently available drugs.

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma